Vanguard Fiduciary Trust
BRTX icon

Vanguard Fiduciary Trust’s BioRestorative Therapies BRTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.2K Buy
181,300
+141,848
+360% +$41.5K ﹤0.01% 3802
2026
Q1 		$10.7K Buy
+39,452
New +$25.3K ﹤0.01% 3994

Other funds holding BRTX

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust's BRTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its BioRestorative Therapies (BRTX) stake by 360% in Q2 2026, buying an estimated $41.5K and bringing the position to 181,300 shares worth $68.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3802.

Vanguard Fiduciary Trust first reported a position in BRTX in Q1 2026 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 181,300 shares of BioRestorative Therapies worth $68.2K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 141,848 BioRestorative Therapies shares in Q2 2026, an estimated $41.5K.
  • BioRestorative Therapies made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3802 holding.
  • Vanguard Fiduciary Trust first reported a position in BioRestorative Therapies in Q1 2026 and has held it in 2 quarters since.
  • 21 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.